SEC Filings

S-1
AVEXIS, INC. filed this Form S-1 on 01/15/2016
Entire Document
 

Table of Contents

to our affiliates, subsidiaries or any successor in interest in connection with a merger, acquisition, consolidation or sale, provided that our assignee assumes our obligations under the NCH License in writing.

          Unless terminated earlier, the licenses expire upon the expiration of the royalty term for each NCH licensed product in each country in which it is sold. The NCH License may be terminated prior to its expiration:

    By us at any time by providing six months' prior written notice to NCH;

    By either party upon the other party's material breach of the NCH License that is not cured within 90 days after receiving written notice of such breach, except in certain cases in which we may request a longer cure period;

    By NCH in the event of our bankruptcy, insolvency or certain similar occurrences; or

    By NCH if we or any of our affiliates bring any action or proceeding against NCH, other than a suit brought in response to any suit brought by NCH.

          Certain accrued payments that we are required to make to NCH will become due in the event of termination as specified in the agreement. As of September 30, 2015, we have reimbursed NCH $0.7 million and incurred $6.1 million in aggregate development costs.

The Research Institute at Nationwide Children's Hospital

          In October 2013, we entered into a clinical trials research agreement with the Research Institute at Nationwide Children's Hospital, or the Research Institute. This agreement governs our preclinical and clinical trials conducted at NCH by Dr. Mendell.

          Under the NCH license agreement, we had the right to elect to become the sponsor of the IND subject to certain reversionary rights of the Research Institute. On October 14, 2015, we entered into an amendment to the NCH License with NCH permitting us to submit to the FDA for the transfer of the IND and associated regulatory filing to us and for us to become the sponsor of such IND. Contemporaneous with the execution of this amendment, we submitted the requisite documents to the FDA to initiate the transfer process. On November 6, 2015, the FDA approved our sponsorship of the IND. We are responsible for all budgeted clinical trial costs that are not covered by grants or certain other sources. All data and information generated under the agreement is subject to our agreements with NCH.

          Unless terminated earlier, the agreement expires upon the completion of the study. The agreement may be terminated prior to its expiration:

    By either party upon the other party's breach of the agreement that is not cured within 60 days after receiving written notice of such breach; or

    By us at any time in the event we elect to become the sponsor of the IND.

          Our clinical trial research agreement with the Research Institute also contains obligations for us to indemnify the Research Institute and its affiliates against certain losses and for us to maintain certain insurance, as well as mutual confidentiality obligations.

REGENXBIO

          In March 2014, we entered into an exclusive license agreement with ReGenX Biosciences, LLC, or ReGenX, predecessor to REGENXBIO Inc., under certain patents and patent applications owned by the Trustees of the University of Pennsylvania and licensed to ReGenX, for

120



© AveXis, Inc. All Rights Reserved.